{"product_id":"diasoringroup-bcg-matrix","title":"DiaSorin Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiaSorin’s BCG Matrix snapshot highlights where its assay franchises likely sit across Stars, Cash Cows, Question Marks, and Dogs, reflecting market growth and relative share in infectious disease and specialty diagnostics; this preview teases product trajectories and resource implications. Purchase the full BCG Matrix for quadrant-by-quadrant placements, data-backed strategic moves, and ready-to-use Word and Excel deliverables to guide investment and portfolio decisions with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLIAISON Plex and Multiplexing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe LIAISON Plex (post-2023 Luminex acquisition) is DiaSorin’s high-growth syndromic profiling play, targeting a molecular diagnostics market growing ~8–10% CAGR; Plex’s customizable panels drove ~15–20% share gains in US clinical labs in 2024.\u003c\/p\u003e\n\u003cp\u003eIts multiplexing flexibility accelerates hospital adoption for faster, integrated results, but scale-up needs CAPEX and R\u0026amp;D; management budgets ~€60–80M 2025–26 to commercialize, making Plex the BCG Matrix star with highest growth potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty CLIA Infectious Disease Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin leads niche infectious-disease CLIA tests—latent TB and specialized viral panels—holding ~25% market share in EU\/US hospital labs and growing revenue ~18% CAGR 2021–25 driven by rising screening mandates (WHO\/CDC) and automated first-to-market assays introduced 2022–24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLIAISON NES and Point-of-Care Molecular\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpanding into decentralized testing with the LIAISON NES point-of-care molecular platform targets a market growing at ~10–12% CAGR to reach $8.5B by 2026, capturing clinics and small labs outside large hospitals.\u003c\/p\u003e\n\u003cp\u003eBy delivering lab-grade molecular accuracy at the point of care, DiaSorin can access new customers; in 2024 point-of-care molecular sales grew ~18%, a channel premium vs central lab pricing.\u003c\/p\u003e\n\u003cp\u003eThis Stars segment demands heavy cash: DiaSorin’s 2024 R\u0026amp;D spend rose to €109M and incremental distribution investments will pressure free cash flow short-term, but are needed to defend diagnostics leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Liquid Biopsy Markers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiaSorin’s oncology and liquid biopsy markers sit in the Stars quadrant: the oncology biomarker market is growing ~14% CAGR to 2028, and DiaSorin’s liquid biopsy rollouts—part of its 2024 R\u0026amp;D push that increased R\u0026amp;D spend to €112m—target high-margin, fast-growing diagnostics in personalized cancer care.\u003c\/p\u003e\n\u003cp\u003eThese tests are in a high-investment phase to capture share before market maturity; pilot adoption shows \u0026gt;30% year‑over‑year growth in clinic use and recurring-revenue potential from monitoring assays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket CAGR ~14% to 2028\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D spend €112m\u003c\/li\u003e\n\u003cli\u003eClinic uptake \u0026gt;30% YoY for pilot assays\u003c\/li\u003e\n\u003cli\u003eHigh-margin, recurring monitoring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioplex 2200 System Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe BioPlex 2200 partnership keeps DiaSorin in the Stars quadrant by securing ~35% global share in multiplex autoimmune testing and driving segment CAGR ~9% (2020–2025), as labs shift from single-analyte to high-throughput panels; shared capital and R\u0026amp;D raise margins to ~28% EBITDA, giving market leadership in a specialized niche.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% global share\u003c\/li\u003e\n\u003cli\u003e~9% CAGR 2020–2025\u003c\/li\u003e\n\u003cli\u003e~28% EBITDA margin\u003c\/li\u003e\n\u003cli\u003eShared resources, high returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiaSorin: Plex, NES \u0026amp; BioPlex Fuel Double‑Digit Growth but €60–80M Capex Strains FCF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin Stars: Plex multiplexing and NES POC drive high growth (~10–15% CAGR) with 2024 R\u0026amp;D €112M; oncology\/liquid biopsy growing ~14% CAGR to 2028 with \u0026gt;30% pilot YoY uptake; BioPlex 35% share, ~9% CAGR, ~28% EBITDA—requires €60–80M 2025–26 capex, pressures FCF but secures market leadership.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€112M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlex\/NES CAGR\u003c\/td\u003e\n\u003ctd\u003e10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology CAGR\u003c\/td\u003e\n\u003ctd\u003e~14% to 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioPlex share\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex 2025–26\u003c\/td\u003e\n\u003ctd\u003e€60–80M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix of DiaSorin products with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each DiaSorin business unit in a quadrant for quick strategic review and decision-making\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBone and Mineral Metabolism (Vitamin D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiaSorin is the global leader in Vitamin D testing, holding roughly 40%–50% share of the €600m global 2024 market for 25(OH)D assays, giving steady high-margin revenue. \u003c\/p\u003e\n\u003cp\u003eThe mature Bone and Mineral Metabolism unit—anchored by the LIAISON immunoassay platform—generates strong free cash flow with low incremental marketing spend; 2024 segment EBITDA margins were near 35%. \u003c\/p\u003e\n\u003cp\u003eThose cash flows funded R\u0026amp;D and capex for molecular diagnostics, supporting DiaSorin’s 2024 group R\u0026amp;D spend of €120m and M\u0026amp;A pipeline investments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Immunodiagnostics Menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Routine Immunodiagnostics menu—chiefly thyroid, fertility, and anemia assays—acts as a cash cow for DiaSorin, holding high market share in low-growth segments (estimated share 30–45% in Europe, 2024 revenue ~€420m for routine assays). \u003c\/p\u003e\n\u003cp\u003eThese tests run on ~20,000 installed LIAISON analyzers worldwide, generating recurring reagent sales with gross margins north of 60%, and covering interest expense and dividend flows (2024 net debt\/EBITDA ~1.2x). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLIAISON XL Installed Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe mature LIAISON XL installed base (over 10,000 analyzers worldwide as of 2025) provides steady cash flow through high-margin, proprietary reagent kits, creating a razor-blade revenue model where consumables drive ~60–65% gross margins and recurring revenue (\u0026gt;50% of DiaSorin’s diagnostics sales in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStool Antigen Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDiaSorin dominates automated stool antigen testing for H. pylori, holding an estimated global market share near 45% in 2024 and supplying high-margin assays in a mature, low-growth segment (projected CAGR ~2% through 2028).\u003c\/p\u003e\n\u003cp\u003eThe automated niche has few new entrants, so stool antigen assays act as a cash cow generating steady operating cash flow—DiaSorin reported €1.1B revenue and ~18% operating margin in FY 2024, funding acquisitions and R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share ~45% (2024)\u003c\/li\u003e\n\u003cli\u003eSegment CAGR ~2% (to 2028)\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue €1.1B; operating margin ~18%\u003c\/li\u003e\n\u003cli\u003eFunds used for M\u0026amp;A and R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensed Technologies and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDiaSorin earns high-margin, low-capex royalties from licensing its bead-based and xMAP-compatible technologies; in 2024 licensing and royalty income contributed about €65m, roughly 8% of group revenue, boosting operating margin.\u003c\/p\u003e\n\u003cp\u003eWidespread industry use of xMAP (over 2,000 labs globally using compatible assays) delivers recurring passive cash flow that strengthens free cash flow and supports R\u0026amp;D and dividends.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 licensing ≈ €65m; ~8% of revenue\u003c\/li\u003e\n\u003cli\u003eMinimal capex; high gross margin\u003c\/li\u003e\n\u003cli\u003exMAP adoption: ~2,000+ labs worldwide\u003c\/li\u003e\n\u003cli\u003eSupports FCF, R\u0026amp;D, shareholder returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiaSorin’s high-margin cash cows fund growth: €1.1B revenue, 18% margin, 1.2x leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiaSorin’s cash cows—Vitamin D, routine immunodiagnostics on ~20,000 LIAISON analyzers, stool antigen assays, and licensing—generated high-margin recurring revenue in 2024 (group revenue €1.1B; operating margin ~18%; R\u0026amp;D €120m), funding molecular diagnostics capex and dividends while keeping net debt\/EBITDA ≈1.2x.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e€1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp. margin\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e€65m (≈8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~1.2x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eDiaSorin BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact DiaSorin BCG Matrix report you'll receive after purchase—no watermarks, no placeholders, just the fully formatted, analysis-ready document designed for strategic clarity and professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview reflects the same market-backed BCG Matrix you’ll download post-purchase, crafted with precision and ready to be edited, printed, or presented to stakeholders without any unexpected changes.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual DiaSorin BCG Matrix file that becomes yours after a one-time purchase, instantly available for immediate application in business planning, investor decks, or competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748287656313,"sku":"diasoringroup-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/diasoringroup-bcg-matrix.png?v=1772207051","url":"https:\/\/matrixbcg.com\/products\/diasoringroup-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}